Tirzepatide
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Tirzepatide and local guidelines before prescribing.
GIP and GLP-1 receptor agonist
Mechanism
Dual GIP and GLP-1 receptor agonist.
Uses
Type 2 diabetes, obesity.
Dosing
- Tirzepatide weekly: A dual GIP/GLP-1 agonist, starting at 2.5 mg and increased in 2.5 mg steps every 4 weeks, to 5–15 mg.
Endocrinology: Diabetes - Tirzepatide Type 2; obesity | 2.5 mg weekly for 4 weeks, increasing by 2.5 mg every 4 weeks to 5–15 mg. Reduces oral contraceptive effectiveness during titration.
Endocrinology: Diabetes - Tirzepatide Obesity | 2.5 mg weekly, increased by 2.5 mg every 4 weeks to 15 mg maximum. NICE TA1026; phased primary care rollout. Reduces oral contraceptive reliability.
Endocrinology: Lipids and obesity
Side effects
Nausea, vomiting, diarrhoea, constipation, pancreatitis, gallstones.
Interactions
Oral contraceptive absorption affected at initiation and dose escalation; insulin and sulfonylureas increase hypoglycaemia.
Contraindications and cautions
Pancreatitis history, medullary thyroid cancer history
Monitoring
HbA1c, weight
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
Caution with dehydration
Overdose and reversal
Supportive
Special advice
Titrate slowly; use additional contraception at starts and escalations.
More from the textbook: uses, cautions and other points
- Weight loss - this can cure mild OSA. GLP-1 based drugs (e.g. tirzepatide) reduce OSA severity.
Respiratory: Sleep and Breathing (Complete) - GLP-1 - from the small bowel after eating; boosts insulin, reduces glucagon, slows stomach emptying and reduces appetite - the basis of semaglutide and tirzepatide for weight loss.
Endocrine: Anatomy Physiology and Pharmacology - Tirzepatide - dual GIP and GLP-1 agonist , weekly injection; greater weight and glucose reduction; similar side effects.
Endocrine: Anatomy Physiology and Pharmacology - Weight-loss medicines: GLP-1 agonists and tirzepatide (see below).
Endocrinology: Diabetes - Early-onset type 2 diabetes (under 40): Consider triple therapy with metformin MR, an SGLT2 inhibitor and a GLP-1 agonist or tirzepatide.
Endocrinology: Diabetes - How incretin drugs work: GLP-1 is a gut hormone released after eating. GLP-1 receptor agonists act on the brain to reduce appetite and increase fullness , slow gastric emptying, and boost insulin when glucose is high. Tirzepatide also activates the GIP receptor (a "twincretin"), which gives greater weight loss.
Endocrinology: Lipids and obesity
Where it is discussed in the book
- Respiratory: Sleep and Breathing (Complete) (1 mention)
- Endocrine: Anatomy Physiology and Pharmacology (6 mentions)
- Endocrinology: Diabetes (7 mentions)
- Endocrinology: Lipids and obesity (7 mentions)
- Gastroenterology: Anatomy Physiology Pharmacology (2 mentions)
- Surgery: Surgical principles and perioperative care (2 mentions)
- Surgery: Upper GI, hepatobiliary and bariatric surgery (1 mention)
- Integrated respiratory chapter (1 mention)
- General Practice: Long-term conditions, multimorbidity and polypharmacy (1 mention)
- Public Health: Prevention, health promotion and behaviour change (1 mention)
- Pathology: Immunopathology, amyloidosis, genetic and environmental disease (1 mention)